Maximus markets several approaches to testosterone care, including an oral product that may appeal to men who do not want injections. The important starting point is the product’s identity. Its oral page describes custom-compounded native testosterone, which is different from an FDA-approved testosterone undecanoate capsule.
This review examines the public offer checked on September 23, 2026. We have not used the service or independently tested its medicine. The aim is to help you bring better questions to a consultation, particularly about laboratory monitoring, pharmacy details, fertility claims, and the cost after an introductory discount ends.
KEEP IN MIND
The useful bits.
- Maximus describes compounded native testosterone, not Kyzatrex.
- The introductory price is different from the continuing rate.
- Fertility and safety claims require evidence for the actual product and outcome.
Name the medicine before comparing the route
Maximus describes its oral medicine as compounded native testosterone. Kyzatrex, an FDA-approved oral product, contains testosterone undecanoate. Both are taken by mouth, but their formulation, evidence, instructions, and approval status cannot be treated as interchangeable. A headline saying oral TRT does not resolve those differences.
FDA does not approve compounded drugs or review each preparation for safety, effectiveness, and quality before marketing. That distinction does not replace an individual medical discussion. Ask why a compounded option is being proposed, what alternatives were considered, which pharmacy will dispense it, and how the clinician will assess your response. Keep the written answer with your medication records.
Sources: Maximus: compounded oral testosterone, plan prices, and laboratory requirements · DailyMed: Kyzatrex oral testosterone undecanoate prescribing information · FDA: understanding the risks of compounded drugs
Read the ordinary rate and the introductory offer
The oral product page displays $249.99 per month for a one-month plan, $199.99 per month for three months, and $149.99 per month for six months. It also advertises a limited $74.99 first-month promotion on the six-month plan, followed by $149.99 per month. Prices may vary with the plan, dose, and state.
A listed monthly equivalent is not enough to establish what is collected at checkout or owed if treatment stops. Confirm the billing schedule, total commitment, refund rules, and cost of any change in prescription. Save the offer and order terms together. A low first payment should not become the number used to estimate an entire year.
Sources: Maximus: compounded oral testosterone, plan prices, and laboratory requirements
Laboratory review is part of the decision
Maximus says testing is required before and during treatment. Its oral page allows submission of qualifying outside results from the preceding six months, subject to the required markers and clinical review. That is not a promise that every recent panel will be accepted or that no repeat test will be needed.
Ask for a list of required tests, the price if your existing results are incomplete, and the timing of the next clinical review. Explain whether an earlier sample was collected while using testosterone or another hormone medicine. A clinician needs that context to interpret the numbers; the age of a laboratory report is only one part of its usefulness.
Sources: Maximus: compounded oral testosterone, plan prices, and laboratory requirements · Endocrine Society: testosterone therapy clinical guidance
Treat marketing outcomes as questions to investigate
The page discusses company research and laboratory changes. Those materials can describe what the company measured, but they do not by themselves prove superior long-term outcomes against every other treatment. A higher testosterone result does not automatically tell you how a particular person will feel or whether a side effect will occur.
Ask what evidence applies to the exact prescribed preparation, who was studied, and how safety was followed. We have not independently validated the company’s outcome claims. Our oral versus injectable guide explains how to compare routes without borrowing evidence from a different medicine simply because both contain testosterone.
Sources: Maximus: compounded oral testosterone, plan prices, and laboratory requirements · Endocrine Society: testosterone therapy clinical guidance
Fertility language deserves particular care
Do not interpret fertility-friendly marketing as a guarantee that sperm production will be preserved. Blood hormone measurements, sperm counts, and the chance of pregnancy are different outcomes. Testosterone treatment can suppress sperm production, and fertility goals should be discussed before starting or changing therapy.
AUA/ASRM guidance advises against testosterone monotherapy for men interested in current or future fertility. Your clinician may need a different evaluation or referral depending on your circumstances. Read our fertility planning guide before relying on a commercial claim about this subject. An add-on medicine should not be assumed to remove every fertility risk.
Sources: Maximus: compounded oral testosterone, plan prices, and laboratory requirements · AUA/ASRM: male infertility guideline, amended 2024
Request one clear instruction sheet
The public page uses differing descriptions of pill routines. We are not reproducing either as a dosing recommendation. The instructions on your prescription and the explanation from your pharmacist should agree. If they do not, get clarification before using the medicine rather than choosing the simpler marketing description.
Also ask how blood pressure, blood counts, symptoms, and medication interactions will be reviewed. Oral treatment does not remove the need for monitoring. The FDA’s class-wide testosterone update reinforces blood-pressure concerns, and a compounded preparation is not exempt from a clinical safety discussion because it avoids a needle.
Sources: Maximus: compounded oral testosterone, plan prices, and laboratory requirements · FDA: 2025 testosterone labeling and blood pressure changes
Where Maximus fits in a provider comparison
Maximus offers enough distinct treatment categories that the first comparison should be prescription against prescription. Its broader menu also includes topical and injectable options and enclomiphene; these should not be collapsed into one interchangeable TRT product. We did not verify that every route is appropriate or available for every applicant.
Our Maximus versus Hone Health comparison separates the oral-product offer from a membership model. Use the route-comparison shortlist if you are still deciding which questions to take to a clinician. Neither a preferred route nor a promotional price establishes that testosterone treatment is indicated.
Sources: Maximus: testosterone treatment options · Hone Health: Basic and Premium memberships and starting assessment
Sources you can check
Provider pages describe commercial offers. Medical references provide context. Checked September 23, 2026; prices and availability can change.
- Maximus: compounded oral testosterone, plan prices, and laboratory requirements
- DailyMed: Kyzatrex oral testosterone undecanoate prescribing information
- FDA: understanding the risks of compounded drugs
- Endocrine Society: testosterone therapy clinical guidance
- AUA/ASRM: male infertility guideline, amended 2024
- FDA: 2025 testosterone labeling and blood pressure changes
- Maximus: testosterone treatment options
- Hone Health: Basic and Premium memberships and starting assessment
Educational information for adults, not a diagnosis or treatment plan. Discuss symptoms and treatment decisions with a licensed clinician. Do not change a prescription based on this article.